About Alchemy
Alchemy gives science-based product teams software for managing laboratory research. It brings their laboratory work into one place.
The company is based in San Francisco. Sasha Novakovich is its co-founder and chief executive officer.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Sep 29, 2026 | Oct 20, 2026 | $1,000,000fully sold | 2 | $500K | Equity, DebtRule 506(b) | Form D ↗ |
| Aug 26, 2022 | Aug 31, 2022 | $2,999,995of $3.0M target | 7 | $428K | EquityRule 506(b) | Form D ↗ |
| Jul 26, 2021 | Aug 2, 2021amended Aug 2, 2021 | $2,999,998of $4.0M target | 7 | $428K | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Apr 7, 2020 | Apr 10, 2020 | $1,150,000of $2.0M target | 5 | $230K | Equity, DebtRule 506(b) | Form D ↗ |
| May 23, 2018 | May 24, 2018 | $4,364,300fully sold | 12 | $363K | EquityRule 506(b) | Form D ↗ |
| Apr 4, 2017 | Apr 19, 2017 | $1,033,120of $2.0M target | 6 | $172K | Debt, Securities on exerciseRule 506(b) | Form D ↗ |
| Total, six offerings | $13,547,413 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Why Investors Backed Alchemy
Alchemy targets product and technical teams at applied science companies. Its software supports their product-development work. The platform covers lab records, sample tracking and formulation work. Its investor appeal may come from that narrow customer focus and broad workflow coverage.
What the product does
The product combines sample-tracking software with a digital notebook for research work. Alchemy calls these tools LIMS and ELN. It also automates formulation workflows. All three functions sit in one platform.
Progress so far
On March 11, 2022, Alchemy expanded its sales team with specialists in food and beverage and energy systems. The hires added experience from two applied science sectors. The expansion also added industry-focused support for research and development labs in those fields.
We wrote this summary from public statements by Alchemy and its investors. It is not investment advice.
Leadership Team
Executive officers and directors listed on Alchemy's Form D filed Oct 20, 2026.
Earlier filings also listed Marko Gacesa (executive officer and director, last listed Aug 2022).